Vidhi Specialty Food Ingredients LtdNSE:VIDHIING
Current view Q1 2027
Makes synthetic food colours; 95% exported, six US-FDA approved. Roha runs full but Dahej only 65–70%, and two pilot plants for pharma coatings and cosmetic pigments commission mid-FY28 on ₹75–85 cr of self-funded capex; manufacturing earns 24.7%. But revenue outgrew profit because the low-margin trading business they spent three years exiting has restarted.
Latest exchange filings last 5 · 5 after Q1 2027
- 1 Sep ’2633rd AGM scheduled for September 24, 2026; annual report and KYC reminder sent to shareholders. ↗
- 1 Sep ’26Pursuant to Reg.30 read with schedule III Part A of LODR we enclose copy of Newspaper publications in Business Standard [English] and Mumbai Lakshadweep [Marathi] … ↗
- 31 Aug ’26Vidhi filed its FY 2025-26 BRSR report with BSE/NSE and posted it online. ↗
- 31 Aug ’26Reg. 34 (1) Annual Report. 31 Aug ↗
- 31 Aug ’26Notice Of The 33Rd Annual General Meeting Of The Company To Be Held On September 24, 2026. 31 Aug ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q1 2027
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q1 2027
| Metric | This year vs lastYoY · vs Q1 2026 | vs the quarter beforeQoQ, sequential · vs Q4 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +65.9% | +18.7% | −2.0% | +7.4% |
| Operating profit | ▲ +23.8% | +23.8% | +12.0% | +7.8% |
| EPS | ▲ +35.0% | +30.4% | +9.1% | +6.0% |
| PAT | ▲ +30.8% | +30.8% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is PAT at +30.8%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Average60/100
Growing, but too slowly to re-price. Profit per share grew 9% a year. A big re-pricing usually needs more than 15% a year, so the score is capped no matter how cheap it looks.
₹354 → ₹708 needs the P/E at 51× — it is 33× today, and has ranged 27× to 74× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 77× — never traded above 74× in 5 years.
Unpaid, but the growth quality is thin. Verify before acting.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a small-cap at ₹1,695 cr, so the odds of a re-rate are not fighting its own size.
Band capped: growth of 9.1% is below the 15% bar a re-rate needs.
Growth rate used: 9.1% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 35%.
How it compares with its rivals Pigments · 6 of 94 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Vidhi Specialty | ₹347 | 32.5× | ₹1,734 Cr | 18.8% | +34.8% | +66.4% |
| Pidilite Inds. | ₹1,596 | 61.4× | ₹1.62 L Cr | 31.0% | +28.2% | +21.3% |
| Gujarat Fluoroch | ₹4,586 | 81.6× | ₹50,373 Cr | 9.6% | +21.4% | +24.0% |
| Navin Fluo.Intl. | ₹8,410 | 54.3× | ₹43,156 Cr | 21.0% | +107.7% | +44.1% |
| Deepak Nitrite | ₹1,605 | 27.6× | ₹21,894 Cr | 11.4% | +207.5% | +36.4% |
| Aether Industri. | ₹1,641 | 90.8× | ₹21,774 Cr | 11.9% | +28.0% | +27.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | yes — a little wider than 3 years earlier | operating margin 16% → 18% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it, with some tied up | 75% last year, 77% over three · free cash flow ₹26 cr, positive in 3 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹58 cr — 0.18× its own equity (was 0.22×) |
| Is it being collected? | collection is steady | 137 days to collect, up 14 in a year · cash cycle 238 days |
| Who has been buying? | the promoters have held steady | promoters 64.3%, 64.3% → 64.3% over 2.8 years · FIIs 0.1% (−0.1) · DIIs 0.0% · shareholders 18,432 → 14,557 |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 18.8% · ROE 15.6% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.
Screener's own checklist not mine, not the score
In its favour
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 38.6%
Against it
- The company has delivered a poor sales growth of 7.36% over past five years.
Generated by screener.in from a fixed checklist — not written by me and not an input to the score. It is here as a second machine opinion to weigh against the note; where it disagrees with the view above, the note is the considered one.